Oral Anticoagulants Market –Opportunity Analysis and Industry Forecast, 2023

Market Highlights

Anticoagulant is a drug, when added to blood, prevents it from clotting. Anticoagulants achieve their effect by suppressing the synthesis or function of various clotting factors that are normally present in the blood. Such drugs are often used to prevent the formation of blood clots (thrombi) in the veins or arteries or the enlargement of a clot that is circulating in the bloodstream.

Increasing cardiovascular disorders, rising geriatric population, and increasing surgical procedures support the growth of the global oral anticoagulants market in recent years. However, the high cost is likely to restrain market growth over the forecast period.

The Global Oral Anticoagulants Market size is expected to grow at CAGR of 12.50% to reach USD 22,561.24 million by 2023

Market Research Future (MRFR) recognizes the following companies as the key players in the global oral anticoagulants market that includes AstraZeneca, Plc (UK), Pfizer (US), Boehringer Ingelheim GmbH (Germany), Daiichi Sankyo Company Ltd (Japan), Abbott Laboratories (US), Eli Lilly and Company (US), GlaxoSmithKline plc (UK) Portola Pharmaceuticals Inc. (US), Medicure (Canada), Johnson & Johnson Services Inc. (US), and others.

Regional Analysis
Geographically, the Americas is expected to dominate the global oral anticoagulants market. This is owing to increasing cardiovascular disorders and increasing surgical procedures.

Europe showed a considerable amount of growth in the market due to the rising geriatric population. Asia-Pacific is estimated to be the fastest growing region in the market. This is owing to increasing cardiovascular disorders and rising geriatric population.

On the other hand, the Middle East & Africa has the least share of the market.

Key Findings of the Study:
• Global oral anticoagulants market is projected to reach USD 22,561.24 million by 2023 with 12.50% CAGR during the review period of 2018 to 2023
• Americas accounted for the largest share due to in the region
• The atrial fibrillation (AF)/stroke prevention segment, is accounted for the largest share, holding a market value of USD 49 in 2017.
• Some of the players operating in the oral anticoagulants market are AstraZeneca, Plc, Pfizer, Boehringer Ingelheim GmbH, Daiichi Sankyo Company Ltd, Abbott Laboratories among others.

https://www.marketresearchfuture.com/reports/oral-anticoagulants-market-7718